<DOC>
	<DOC>NCT00969917</DOC>
	<brief_summary>The primary objective of the study is to determine the safety profile and overall response rate of IPI 504 in patients with advanced dedifferentiated liposarcoma.</brief_summary>
	<brief_title>Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma</brief_title>
	<detailed_description />
	<mesh_term>Liposarcoma</mesh_term>
	<criteria>At least 18 years of age at the time of signing informed consent. Histologic diagnosis of dedifferentiated liposarcoma. Available archival pathology specimen or tissue sample from a new biopsy for confirmation of diagnosis by central pathology reading. At least one prior chemotherapy regimen for dedifferentiated liposarcoma. No more than 2 prior chemotherapy regimens for dedifferentiated liposarcoma. Note: Any number of nonchemotherapy regimens is permitted. Measurable disease on computed tomography (CT) or magnetic resonance imaging (MRI) as defined by RECIST (version 1.1) with at least one measurable lesion. Eastern Cooperative Oncology Group (ECOG) performance status: 0 or 1. Life expectancy â‰¥6 months. Prior treatment with any heat shock protein 90 (Hsp90) inhibitor. Surgery, radiotherapy, or lesion ablative procedure to the only area of measurable disease Patients with prior hepatic resections or hepaticdirected therapy Use of a medication or food that is a clinically relevant CYP3A inhibitor or inducer within 2 weeks prior to dosing.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>